• 1
    Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepat. 2004; 11: 97107.
  • 2
    Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988; 61: 19421956.
  • 3
    Tran TT, Martin P. Hepatitis B: epidemiology and natural history. Clin. Liver Dis. 2004; 8: 255266.
  • 4
    Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43: S99112.
  • 5
    Hirsch HA, Iliopoulus D, Joshi A et al. A transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseases. Cancer Cell 2010; 17: 348361.
  • 6
    Caballeria L, Pera G, Rodriguez L et al. Metabolic syndrome and nonalcoholic fatty liver disease in a Spanish population: influence of the diagnostic criteria used. Eur. J. Gastroenterol. Hepatol. 2012; 24: 10071011.
  • 7
    Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day C. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004; 126: 586597.
  • 8
    Pekow JR, Bahn AK, Zheng H, Chung RT. Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. Cancer 2007; 109: 24902496.
  • 9
    Soresi M, Tripi S, Franco V et al. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis. Liver Int. 2006; 26: 11191125.
  • 10
    Peng D, Han Y, Ding H, Wei L. Hepatic steatosis in chronic hepatitis B patients is associated with metabolic factors more than viral factors. J. Gastroenterol. Hepatol. 2008; 23: 10821088.
  • 11
    Shi JP, Fan JG, Wu R et al. Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infections. J. Gastroenterol. Hepatol. 2008; 23: 14191425.
  • 12
    Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients. J. Gastroenterol. Hepatol. 2011; 26: 13611367.
  • 13
    Wong VW, Wong GL, Chu WC et al. Hepatitis B virus infection and fatty liver in the general population. J. Hepatol. 2012; 56: 533540.
  • 14
    Wong GL, Wong VW, Choi PC et al. Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. Gut 2009; 58: 111117.
  • 15
    Park SH, Kim DJ, Lee HY. Insulin resistance is not associated with histologic severity in nondiabetic, noncirrhotic patients with chronic hepatitis B virus infection. Am. J. Gastroenterol. 2009; 104: 11351139.
  • 16
    Poynard T, Ngo Y, Munteanu M, Thabut D, Ratziu V. Noninvasive markers of hepatic fibrosis in chronic hepatitis B. Curr. Hepat. Rep. 2011; 10: 8797.
  • 17
    Vigano M, Paggi S, Lampertico P et al. Dual cut-off transient elastography to assess liver fibrosis in chronic hepatitis B: a cohort study with internal validation. Aliment. Pharmacol. Ther. 2011; 34: 353362.
  • 18
    Oliveri F, Coco B, Ciccorossi P et al. Liver stiffness in the hepatitis B virus carrier: a non-invasive marker of liver disease influenced by the pattern of transaminases. World J. Gastroenterol. 2008; 14: 61546162.
  • 19
    Maimone S, Calvaruso V, Pleguezuelo M et al. An evaluation of transient elastography in the discrimination of HBeAg-negative disease from inactive hepatitis B carriers. J. Viral Hepat. 2009; 16: 769774.
  • 20
    European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J. Hepatol. 2012; 57: 167185.
  • 21
    Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661662.
  • 22
    Papatheodoridis GV, Manolakopoulos S, Liaw YF, Lok A. Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: a systematic review. J. Hepatol. 2012; 57: 196202.
  • 23
    Alberti KG, Eckel RH, Grundy SM et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 16401645.
  • 24
    Martinot-Peignoux M, Boyer N, Colombat M et al. Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers. J. Hepatol. 2002; 36: 543546.
  • 25
    Kumar M, Sarin SK, Hissar S et al. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology 2008; 134: 13761384.
  • 26
    Fateen AA, Shahin RY, Farres MN, Eldeeb MA, Amer HA. Assessment of hepatic fibrosis and necroinflammation among inactive HBsAg carriers in Egypt. Ann. Hepatol. 2012; 11: 464470.
  • 27
    Smits MM, Ioannou GN, Boyko EJ, Utzschneider KM. Non-alcoholic fatty liver disease as an independent manifestation of the metabolic syndrome: results of a US national survey in three ethnic groups. J. Gastroenterol. Hepatol. 2013; 28: 664670.
  • 28
    Luksiene DI, Beceviciene M, Tamosiunas A, Cerniauskiene LR, Margeviciene L, Reklaitiene R. Prevalence of the metabolic síndrome diagnosed using three different definitions and risk of ischemic heart disease among Kaunas adult population. Medicina (Kaunas) 2010; 46: 6169.
  • 29
    Marcellin P, Ziol M, Bedossa P et al. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int. 2009; 29: 242247.
  • 30
    Roulot D, Czernichow S, Le Clesiau H, Costes JL, Vergnaud AC, Beaugrand M. Liver stiffness values in apparently healthy subjects: influence of gender and metabolic syndrome. J. Hepatol. 2008; 48: 606613.
  • 31
    Malik R, Afdhal N. Stiffness and impedance: the new liver biomarkers. Clin. Gastroenterol. Hepatol. 2007; 5: 12141220.
  • 32
    Fraquelli M, Branchi F. The role of transient elastography in patients with hepatitis B viral disease. Dig. Liver Dis. 2012; 43 (Suppl. 1): S2531.
  • 33
    Asselah T, Rubbia-Brandt L, Marcellini P, Negro F. Steatosis in chronic hepatitis C: why does it really matter? Gut 2006; 55: 123130.
  • 34
    Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004; 126: 586597.
  • 35
    Hui JM, Sud A, Farrell GC et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 2003; 125: 16951704.
  • 36
    Kumar M, Choudhury A, Manglik N et al. Insulin resistance in chronic hepatitis B virus infection. Am. J. Gastroenterol. 2009; 104: 7682.
  • 37
    Wong GL, Chan HL, Yu Z, Chan HY, Tse CH, Wong VW. Liver fibrosis progression is uncommon in patients with inactive chronic hepatitis B—a prospective cohort study with paired transient elastography examinatiom. J. Gastroenterol. Hepatol. 2013; 28: 18421848.